Neoadjuvant chemotherapy (NACT) use in triple-negative breast cancer (TNBC) increased from 19.1% to 56.4% between 2010 and 2021, with pathologic complete response (pCR) rates rising from 19.6% to ...

AstraZeneca’s first-in-class pan-AKT inhibitor Truqap was unable to improve overall survival (OS) in a phase 3 trial in triple-negative breast cancer (TNBC), denting the prospects of the new drug.

Not just any breast cancer—this one targets triple-negative breast cancer (TNBC), the most aggressive and hardest to treat. Unlike other vaccines, it doesn’t just help the immune system ...

A recent study from Necmettin Erbakan University has identified a protein called CRELD2 as a possible biomarker for predicting survival in patients with triple-negative breast cancer (TNBC)—one of the ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Researchers at Baylor College of Medicine showed ...

Merck & Co has claimed EU approval for Keytruda in triple-negative breast cancer (TNBC), a particularly hard-to-treat form of the disease. The European Commission has cleared Keytruda ...

Penetrium inhibits this niche formation, preventing metastatic cells from successfully colonizing new sites. This TNBC study represents the first experimental evidence that Penetrium effectively ...

A new study published in the journal Immunity reveals a mechanism that allows triple negative breast cancer (TNBC) to develop resistance to therapy. Standard-of-care treatment for TNBC includes ...